

LEUKEMIA AND ALLIED DISORDERS 2023

VIRTUAL

May 25-26, 2023

Coordinators: Angelo M. Carella, Sergio Amadori



AUSPICES:



ASSOCIAZIONE ITALIANA
CONTRO LEUCEMIE
E LINFOME MIELOIDE



fondazione GIMEMA onlus
per la promozione e lo sviluppo della ricerca scientifica
sulle malattie ematologiche. **FRANCO MANDELLI**



GRUPPO ITALIANO TRAPIANTI DI MIDOLLO OSSEO



SIE
Società Italiana
di Ematologia

LEUKEMIA AND ALLIED DISORDERS 2023

VIRTUAL

May 25-26, 2023

Coordinators: Angelo M. Carella, Sergio Amadori

Welcome message

We welcome you to the 12th annual conference on leukemia. We are very pleased to inform you that the conference will be held under the aegis of AIL, GIMEMA Foundation, GITMO, SIE and SIES. The aim of the conference is to bring together highly qualified Italian experts to discuss emerging paradigms and breakthroughs at the forefront of biology and treatment across the spectrum of blood cancers, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative disorders, lymphomas and myelomas and update results with CAR-T and monoclonal antibodies. Attendees will hear of recent findings in basic and clinical research, from the molecular basis of blood cancers to novel therapies emerging in the clinic, through ample interaction with key experts in the field.

SERGIO AMADORI



ANGELO MICHELE CARELLA



SCIENTIFIC BOARD

Francesca Bonifazi
Antonio Cuneo
Franco Locatelli
Fabrizio Pane
Alessandro Rambaldi
Valeria Santini
Alessandro M. Vannucchi



Faculty

Mattia
Sergio
Francesca
Francesco
Alessandro
Anna
Angelo Michele
Angelo Michele
Michele
Mario
Sabina
Paolo
Antonio
Antonio
Valerio
Francesca
Matteo Giovanni
Bruno
Robin
Sara
Umberto
Paola
Fabio
Adalberto
Roberto
Franco
Federico
Maurizio
Esther Natalie
Atilio
Fabrizio
Francesco
Francesca
Antonio
Giovanni
Concetta
Alessandro
Luigi
Gian Matteo
Carmelo
Valeria
Lydia
Simona
Alessandro M.
Adriano
Marco
Andrea
Renato
Pier Luigi

ALGERI
AMADORI
BONIFAZI
BUCCISANO
BUSCA
CANDONI
CARELLA
CARELLA JR.
CAVO
CAZZOLA
CHIARETTI
CORRADINI
CUNEO
CURTI
DE STEFANO
DEL BUFALO
DELLA PORTA
FATTIZZO
FOÀ
GALIMBERTI
GIANELLI
GUGLIELMELLI
GUOLO
IBATICI
LATAGLIATA
LOCATELLI
LUSSANA
MARTELLI
OLIVA
OLIVIERI
PANE
PASSAMONTI
PATRIARCA
PIERINI
PIZZOLO
QUINTARELLI
RAMBALDI
RIGACCI
RIGOLIN
RIZZARI
SANTINI
SCARFÒ
SICA
VANNUCCHI
VENDITI
VIGNETTI
VISENTIN
ZAMBELLO
ZINZANI

Rome, Italy
Rome, Italy
Bologna, Italy
Rome, Italy
Turin, Italy
Modena, Italy
Genoa, Italy
San Giovanni Rotondo (FG), Italy
Bologna, Italy
Pavia, Italy
Rome, Italy
Milan, Italy
Ferrara, Italy
Bologna, Italy
Rome, Italy
Rome, Italy
Rozzano (MI), Italy
Milan, Italy
Rome, Italy
Pisa, Italy
Milan, Italy
Florence, Italy
Genoa, Italy
Genoa, Italy
Rome, Italy
Rome, Italy
Bergamo, Italy
Rome, Italy
Reggio Calabria, Italy
Ancona, Italy
Naples, Italy
Varese, Italy
Udine, Italy
Perugia, Italy
Verona, Italy
Rome, Italy
Bergamo, Italy
Rome, Italy
Ferrara, Italy
Milan, Italy
Florence, Italy
Milan, Italy
Rome, Italy
Florence, Italy
Rome, Italy
Rome, Italy
Padua, Italy
Padua, Italy
Bologna, Italy

Thursday, May 25, 2023

09.30 am **Opening Ceremony**

09.45 am **GIMEMA**

Ongoing clinical trials and future developments of the hematological no profit research

M. Vignetti

10.00 am **SYMPOSIUM**

Chairmen: **M. Martelli, L. Rigacci**

Bispecific antibodies in lymphomas and myeloma

F. Patriarca,
P.L. Zinzani

11.00 am **Break**

SESSION I CAR-T

Chairmen: **P. Corradini, F. Locatelli**

11.15 am Allogeneic CAR-T cells in BCP-ALL

F. Del Bufalo

11.30 am CAR-T cells in T-ALL

F. Locatelli

11.45 am CAR-T cells in multiple myeloma

M. Cavo

12.00 pm New indications of CAR-T cells in NHL lymphoma

P. Corradini

12.15 pm Pre-clinical development of CD123-targeting NK cells

C. Quintarelli

12.30 pm CAR-CIK cells for patients with MRD relapsed disease

A. Rambaldi

12.45 pm *Discussion*

01.00 pm **Break**

SESSION II MYELOPROLIFERATIVE NEOPLASMS

Chairmen: **A. Ibatì, A.M. Vannucchi**

01.45 pm Interpreting the new classifications (WHO, ICC) for myeloproliferative neoplasms

U. Gianelli

02.00 pm The significance of molecular response in MPN

P. Guglielmelli

02.15 pm Novel concepts for thrombosis risk stratification in PV

V. De Stefano

02.30 pm Combination therapies in myelofibrosis

F. Passamonti

02.45 pm *Discussion*

SESSION III MYELODISPLASTIC SYNDROME

Chairmen: **M.G. Della Porta, V. Santini**

03.00 pm MDS and autoimmune diseases

B. Fattizzo

03.15 pm Management of MDS with T-LGL

R. Zambello

03.30 pm Novel approaches to therapy of anemia in MDS

R. Latagliata

03.45 pm Novel approaches to therapy of thrombocytopenia in MDS

E.N. Oliva

04.00 pm *Discussion*

04.15 pm **Break**

04.30 pm **FRANCO MANDELLI LECTURE**

Introduced by S. Amadori

M. Cazzola

SESSION IV ACUTE MYELOID LEUKEMIA

Chairmen: **F. Pane, A. Venditti**

05.00 pm The novel genomic classifications (ELN and ICC) of acute myeloid leukemia in adults: what is changing?

F. Guolo

05.15 pm Selecting therapy for acute myeloid leukemia with or without predictive biomarkers or therapeutically actionable genomic or molecular alterations

A. Candoni

05.30 pm Measurable residual disease in acute myeloid leukemia. Technical and prognostic issues and the role of post consolidation therapy

F. Buccisano

05.45 pm Novel adaptive immune therapies and innate immune modifier drug to target acute myeloid leukemia

A. Curti

06.00 pm *Discussion*

Friday, May 26, 2023

09.00 am	JOHN GOLDMAN LECTURE Introduced by A.M. Carella	R. Foà
SESSION V	ACUTE LYMPHOBLASTIC LEUKEMIA Chairmen: A.M. Carella Jr., A. Rambaldi	
09.30 am	Asparaginase an old drug for the modern treatment of ALL	C. Rizzari
09.45 am	Prophylaxis and treatment of leukemia relapse after allogeneic stem cell transplantation	F. Lussana
10.00 am	Translational research within clinical trials of the GIMEMA study group	S. Chiaretti
10.15 am	When viruses meet fungi: tackling the enemies in ALL before and after transplantation	A. Busca
10.30 am	<i>Discussion</i>	
SESSION VI	CHRONIC LYMPHOCYTIC LEUKEMIA Chairmen: A. Cuneo, G. Pizzolo	
10.45 am	MRD detection in chronic lymphocytic leukemia: flow cytometry and PCR	S. Galimberti
11.00 am	Genomic complexity as a prognostic/predictive factor	G.M. Rigolin
11.15 am	Drivers of therapeutic decision in patients with and without TP53 aberrations	A. Visentin
11.30 am	Treatment options in relapsed/refractory CLL after covalent BTK inhibitors and venetoclax	L. Scarfò
11.45 am	<i>Discussion</i>	
SESSION VII	GVHD: WHERE DO WE STAND? Chairmen: F. Bonifazi, A. Olivieri	
12.00 pm	Perspectives and limits of post-transplant cyclophosphamide	S. Sica
12.15 pm	Perspectives and limits of ATG/ATLG	F. Bonifazi
12.30 pm	Perspectives and limits of ex vivo T-cell depletion in adults	A. Pierini
12.45 pm	Perspectives and limits of ex vivo T-cell depletion in children	M. Algeri
01.00 pm	<i>Discussion</i>	
01.15 pm	Closing Remarks	

with unrestricted educational grant of:

abbvie

AMGEN®

AstraZeneca 

 BeiGene

 | **SOLVE ON.**

janssen  Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

 Roche

SERVIER 
moved by you

 **MENARINI** Stemline

INFORMAZIONI GENERALI

ISCRIZIONE

La registrazione è gratuita e si effettua dal sito www.leukemia2023.it entro il 24 maggio 2023. Al termine dell'iscrizione verrà inviata un'email di conferma con le credenziali di accesso alla FAD. Per accedere alla FAD il giorno dell'evento, cliccare sulla sezione FAD presente sul sito: www.leukemia2023.it, inserendo le credenziali ricevute via email.

LINGUA

Il meeting si terrà in lingua italiana.

ECM - FAD SINCRONA

La FAD sincrona prevede la partecipazione all'attività formativa attraverso una piattaforma multimediale dedicata (webinar), che sarà fruibile in diretta attraverso una connessione ad internet. La sincronicità della partecipazione prevede il collegamento dei discenti agli orari prestabiliti dal programma formativo, garantendo l'interattività con i docenti attraverso un sistema di messaggistica. La partecipazione viene rilevata attraverso la registrazione degli accessi alla piattaforma durante la sessione di formazione che verrà registrata e resa disponibile per una fruizione asincrona/ripetibile, come supporto alla compilazione del questionario ECM. La verifica di apprendimento verrà effettuata tramite il questionario da effettuare entro 3 giorni dalla data dell'evento.

Il Congresso è stato accreditato presso il Ministero della Salute come segue:

- Provider Studio ER Congressi Srl - ID 828- 382775
- **N. 16,5 crediti formativi** per la figura di Medico Chirurgo (discipline: ematologia, medicina interna, oncologia, patologia clinica - laboratorio di analisi chimico-cliniche e microbiologia), Biologo
- Obiettivo Formativo: linee guida-protocolli-procedure

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy
Ph +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it